Biomarker ID | 162 |
PMID | 16618727 |
Year | 2006 |
Biomarker | SMPDL3B (Sphingomyelinase like phosphodiesterase 3B) [SMPDL3B 2030] |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-NRK human kinase ARCHS4 coexpression, ROR1 human kinase ARCHS4 coexpression,EPHA1 human kinase ARCHS4 coexpression |
Experiment | Cancerous Tissue Vs Normal Tissue |
Type of Biomarker | Diagnostic |
Cohort | Two sets of Patients were included in the study. Set 1 included 10 cancerous, and 6 normal tissues. Set 2 included 12 cancerous and 10 normal tissues |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | 2.32E-08 |
Method Used | RT-PCR and qPCR |
Clinical | No |
Remarks | Brackets indicate ISOFORMS of the mRNA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | SMPDL3B |